Safety and Tolerability of Donepezil at Doses up to 20 mg/dayResults from a Pilot Study in Patients with Alzheimer’s Disease

被引：0
|
作者：
Rachelle S. Doody
Jody Corey-Bloom
Richard Zhang
Honglan Li
John Ieni
Rachel Schindler
机构：
[1] Baylor College of Medicine,Alzheimer’s Disease and Memory Disorders Center
[2] UCSD School of Medicine,Department of Neurosciences
[3] Pfizer Inc.,undefined
[4] Eisai Inc.,undefined
来源：
Drugs & Aging | 2008年 / 25卷
关键词：
Rivastigmine; Galantamine; Last Observation Carry Forward; Psychometric Measure; Adverse Event Monitoring;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Donepezil is licensed for the treatment of mild-to-moderate Alzheimer’s disease (AD) at doses of 5–10 mg/day and has recently been approved in the US for severe AD. Multiple studies have suggested that donepezil 10 mg/day provides additional cognitive and functional benefits over the 5 mg/day dose. Higher doses of donepezil, if safe and well tolerated, might provide further benefits for patients with AD.
引用
下载
收藏
页码：163 / 174
页数：11
相关论文
共 50 条
  • [31] Donepezil Enhances Frontal Functional Connectivity in Alzheimer's Disease: A Pilot Study
    Griffanti, Ludovica
    Wilcock, Gordon K.
    Voets, Natalie
    Bonifacio, Guendalina
    Mackay, Clare E.
    Jenkinson, Mark
    Zamboni, Giovanna
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2016, 6 (03): : 518 - 528
  • [32] Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients
    Zhang, Nan
    Gordon, Marc L.
    CLINICAL INTERVENTIONS IN AGING, 2018, 13 : 1963 - 1970
  • [33] Efficacy and Safety of Donepezil in Patients With Alzheimer's Disease in Assisted Living Facilities
    Rosenblatt, Adam
    Gao, Jeff
    Mackell, Joan
    Richardson, Sharon
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2010, 25 (06): : 483 - 489
  • [34] A pilot study on the efficacy, tolerability and safety of safinamide in elderly Parkinson's disease patients
    Rinaldi, D.
    Sforza, M.
    Bianchini, E.
    Galli, S.
    Pontieri, F. E.
    MOVEMENT DISORDERS, 2020, 35 : S477 - S477
  • [35] Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
    Alan G Wade
    Gordon M Crawford
    Ann Yellowlees
    BMC Psychiatry, 11
  • [36] Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
    Wade, Alan G.
    Crawford, Gordon M.
    Yellowlees, Ann
    BMC PSYCHIATRY, 2011, 11
  • [37] Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease
    Han, S. -H.
    Lee, J. -H.
    Kim, S. Y.
    Park, K. W.
    Chen, C.
    Tripathi, M.
    Dash, A.
    Kubota, N.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 135 (02): : 252 - 256
  • [38] Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil
    Auriacombe, S
    Pere, JJ
    Loria-Kanza, Y
    Vellas, B
    CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (03) : 129 - 138
  • [39] Long-Term Safety And Tolerability Of Escalating Doses Of Crenezumab In Patients With Mild-To-Moderate Alzheimer's Disease
    Asnaghi, Veronica
    Lin, Helen
    Rabbia, Michael
    Ostrowitzki, Susanne
    Smith, Jillian
    Cho, Wiliam
    NEUROLOGY, 2017, 88
  • [40] Safety and tolerability of metrifonate in patients with Alzheimer's disease: Results of a maximum tolerated dose study
    Cutler, NR
    Jhee, SS
    Cyrus, P
    Bieber, F
    TanPiengco, P
    Sramek, JJ
    Gulanski, B
    LIFE SCIENCES, 1998, 62 (16) : 1433 - 1441
12345